Discovery of a small-molecule NDR1 agonist for prostate cancer therapy
Yang Bai,Xiuyuan Sui,Zuodong Xuan,Yifan Du,Meiling Fu,Zeyuan Zheng,Kunao Yang,Chunlan Xu,Yankuo Liu,Bin Liu,Min Zhong,Zhengying Zhang,Jianzhong Zheng,Xiaoyan Hu,Lei Zhang,Huimin Sun,Chen Shao
DOI: https://doi.org/10.3389/fphar.2024.1367358
IF: 5.6
2024-02-13
Frontiers in Pharmacology
Abstract:Prostatic cancer (PCa) is a common malignant neoplasm in men worldwide. Most patients develop castration-resistant prostate cancer (CRPC) after treatment with androgen deprivation therapy (ADT), usually resulting in death. Therefore, investigating new therapeutic targets and drugs for PCa patients is urgently needed. Nuclear Dbf2-related kinase 1 (NDR1), also known as STK38, is a serine/threonine kinase in the NDR/LATS kinase family that plays a critical role in cellular processes, including immunity, inflammation, metastasis, and tumorigenesis. It was reported that NDR1 inhibited the metastasis of prostate cancer cells by suppressing epithelial-mesenchymal transition (EMT), and decreased NDR1 expression might lead to a poorer prognosis, suggesting the enormous potential of NDR1 in antitumorigenesis. In this study, we characterized a small-molecule agonist named aNDR1, which specifically bound to NDR1 and potently promoted NDR1 expression, enzymatic activity and phosphorylation. aNDR1 exhibited drug-like properties, such as favorable stability, plasma protein binding capacity, cell membrane permeability, and PCa cell-specific inhibition, while having no obvious effect on normal prostate cells. Meanwhile, aNDR1 exhibited good antitumor activity both in vitro and in vivo . aNDR1 inhibited proliferation and migration of PCa cells and promoted apoptosis of PCa cells in vitro . We further found that aNDR1 inhibited subcutaneous tumors and lung metastatic nodules in vivo , with no obvious toxicity to the body. In summary, our study presents a potential small-molecule lead compound that targets NDR1 for clinical therapy of PCa patients.
pharmacology & pharmacy